Opus Genetics (Nasdaq: IRD) is a clinical-stage ophthalmic biopharmaceutical company developing therapies to treat patients with inherited retinal diseases (IRDs) and other treatments for ophthalmic disorders.

This company webcast was recorded during the Lytham Partners Spring 2025 Investor Conference.